Thery Pharm Raises ￥250M in Series C Round

According to VCBeat, in September 2020, Thery Pharm, a unicorn company in Suzhou, has raised nearly 250 million yuan in the Series C financing round, jointly led by SND Ventures Group and CEC Capital, with additional support from new investors including Sushang Fund under Jinpu Investment, Yingjia and Talent Fund under SID Venture Capital, Taihao Capital under SND Group and Dunxing Venture Capital. The existing shareholder Legend Capital also participated in the fresh round.

Proceeds from the latest round will be used to improve the pipeline, accelerate the development of drugs, and enhance the independent R&D ability of drugs.

Since its establishment in 2010, Thery Pharm is committed to the R&D, production and sales of characteristic API and high-end reagents, and has formed a rich pipeline. Its projects under development cover the fields of anti-tumor, digestive conditions, cardio-cerebrovascular, polypeptide and anti-virus, etc., with 7 reagents and 14 API products approved to market, and 11 products having clinical approvals. Among them, many API products have got the certification of EU and FDA.

Thery Pharm possesses API technologies such as crystallization and purification, green synthesis and complex synthesis of modules with multi chiral centers. Based on the technologies, the company has also built three synthesis platforms for multi-unit sustained-release pellets, oral polypeptide and long-acting injection.

SND Ventures Group is a venture capital and private equity firm specializing in seed investments. The company was established in July 2008 with a registered capital of RMB 940 million. The Group provides equity investments (angel investment, VC investment, PE investment, industrial investment, M&A investment) and other financial services.

Founded in 2000, CEC Capital is a leading investor in China with a focus on the TMT, consumer and healthcare sectors.Headquartered in Beijing with offices in Shanghai, Los Angeles, and San Francisco, the company provides M&A, capital raising, and asset management services to our clients both in and outside of China. CEC Capital is currently managing an RMB fund and a US dollar fund, with a total AUM close to $500 million.